Background-Atopaxar (E5555) is a reversible protease-activated receptor-1 thrombin receptor antagonist that interferes with platelet signaling. The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT-ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS. Methods and Results-Six hundred and three subjects were randomized within 72 hours of non-ST-elevation ACS to 1 of 3 doses of atopaxar (400-mg loading dose followed by 50, 100, or 200 mg daily) or matching placebo. The incidence of Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) major or minor bleeding did not differ significantly between the combined atopaxar and placebo groups (3.08% versus 2.17%, respectively; Pϭ0.63), and there was no dose-related trend (Pϭ0.80). The incidence of CURE major bleeding was numerically higher in the atopaxar group compared with the placebo group (1.8% versus 0%; Pϭ0.12). The incidence of cardiovascular death, myocardial infarction, stroke, or recurrent ischemia was similar between the atopaxar and placebo arms (8.03% versus 7.75%; Pϭ0.93). The incidence of CV death, MI, or stroke was 5.63% in the placebo group and 3.25% in the combined atopaxar group (Pϭ0.20). Dose-dependent trends for efficacy were not seen. Atopaxar significantly reduced ischemia on continuous ECG monitoring (Holter) at 48 hours compared with placebo (relative risk, 0.67; Pϭ0.02). Transient dose-dependent transaminase elevation and relative QTc prolongation were observed with the highest doses of atopaxar. Conclusion-In patients after ACS, atopaxar significantly reduced early ischemia on Holter monitoring without a significant increase in major or minor bleeding. Larger trials are required to fully establish the efficacy and safety of atopaxar. Clinical Trial Registration-URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00548587.
significant interindividual variability in pharmacodynamic response. 6 
Editorial see p 1833 Clinical Perspective on p 1853
Thrombin has been identified as the most potent physiological platelet agonist, 7 and its production is increased after ACS. 8 Thrombin can stimulate platelet activation via the protease-activated receptor-1 (PAR-1) receptor on the platelet cell surface. Because aspirin and P2Y 12 receptor antagonists do not interfere with PAR-1-dependent platelet activation, patients on standard dual antiplatelet therapy remain at risk of recurrent cardiovascular events because of alternative pathways of platelet activation.
Atopaxar (E5555) is an orally active, reversible, smallmolecule inhibitor that selectively inhibits PAR-1 activation by binding at or near the tethered ligand binding site. Because atopaxar selectively interferes with thrombin-mediated platelet activation without disrupting thrombin-dependent fibrin generation or ADP-dependent platelet activation, atopaxar may provide a therapeutic option with diminished risk of bleeding compared with traditional antithrombotic and antiplatelet drugs.
The primary objective of the multicenter, international, phase II Lessons from Antagonizing the Cellular Effects of Thrombin (LANCELOT)-ACS trial was to evaluate the safety and tolerability of atopaxar in patients after ACS. This trial was conducted in parallel with LANCELOT-CAD, a phase II trial of atopaxar in patients with stable coronary artery disease.
Methods

Study Design and Participants
The LANCELOT-ACS trial was a randomized, double-blind, placebo-controlled phase II trial. The study enrolled 603 subjects at 184 sites in 22 countries between March 17, 2008 , and June 9, 2009. Subjects were eligible for enrollment if they were between 18 and 80 years of age and had been hospitalized in the past 72 hours with signs and symptoms consistent with non-ST-elevation ACS (unstable angina or myocardial infarction [MI] without persistent ST-segment elevation). All subjects were required to have new onset or a worsening pattern of ischemic symptoms either at rest or with minimal activity. Subjects were required to have either elevated biomarkers of myonecrosis (troponin or creatine kinase-MB) or ECG changes suggestive of ischemia (ST-segment depression at least 1 mm in 2 contiguous leads, T-wave inversion of Ͼ3 mm, dynamic ST-segment shift, or transient ST-segment elevation). Investigators were encouraged to treat subjects according to the existing practice guidelines.
Key exclusions included an increased risk of bleeding, anemia (hemoglobin Ͻ10 g/dL), thrombocytopenia (Ͻ100ϫ10 3 /L), a recent history of ischemic stroke or transient ischemic attack (Ͻ12 months), or a history of pathological intracranial findings (including a history of intracranial bleeding or known structural cerebral vascular lesion). Those subjects requiring planned major elective surgery during the course of the study were excluded from participation. Patients were excluded if they were to receive oral antiplatelet drugs other than aspirin (Յ325 mg daily), clopidogrel (75 mg daily; any loading dose allowed), or ticlopidine (250 mg twice daily) during follow-up. The use of a glycoprotein IIb/IIIa inhibitor was allowed at the physician's discretion. The use of oral anticoagulants (eg, warfarin, acenocoumarol), fibrinolytics, or regular nonsteroidal anti-inflammatory drugs was prohibited. Patients with known hepatic disease or a creatinine clearance Ͻ30 mL/min were excluded. The study was performed in accordance with local ethics regulations, and all subjects provided written informed consent. The study was registered (www.clinicaltrials.gov; unique identifier, NCT00548587.
Procedures
Subjects were randomized 1:1:1:1 to treatment with 1 of 3 dosing levels of atopaxar (400-mg loading dose followed by 50, 100, or 200 mg daily) or matching placebo (Figure 1 ). Investigators and participants were blinded to treatment assignment. Subjects were to be treated for 12 weeks and followed up for an additional 4 weeks after discontinuation of therapy. An independent Data Monitoring Committee reviewed unblinded data to assess patient safety. If a subject required any major surgery or major invasive procedure during the course of the trial, the study drug was to be discontinued at least 7 days before the procedure. Subjects were to continue study drug if they required cardiac catheterization or percutaneous coronary intervention.
Because of a programming error in the interactive voice response system during the course of the trial, some subjects were dispensed the incorrect dose of study medication. As a consequence, 78 subjects in the 100-mg and 200-mg atopaxar dose arms (38 in the 100-mg group and 40 in the 200-mg group) were erroneously dispensed the 50-mg dose of atopaxar at the week 4 visit. Of these individuals, 21 subjects were resupplied with the correct dose of study drug before the study conclusion, and their median exposure time to the incorrect dose was 28 days. No subjects in the placebo or 50-mg dose arms were affected by the programming error.
Electrocardiographic Monitoring
A 12-lead ECG was performed at all study visits and reviewed centrally. Continuous 12-lead ECG (Holter) monitoring was to be performed in all subjects for the first 48 hours after randomization or until hospital discharge, whichever came first. The data were forwarded to a core laboratory for analysis (Biomedical Systems, Brussels, Belgium) and then overread by at least 2 independent cardiologists who were blinded to the treatment assignment. Recurrent ischemia by continuous ECG monitoring was defined as horizontal or downsloping ST-segment depression Ն0.1 mV below the baseline or upward ST-segment elevation Ն0.1 mV above the baseline that lasted Ն1 minute and was separated from other episodes by Ն1 minute. The data were combined across active treatment arms because a common loading dose was used in all groups.
Platelet Function Testing
Platelet aggregation was assessed by light transmission aggregometry with the PAP-8 aggregometer (BioData Corp, Hatboro, PA) at selected study sites by a specially trained, independent, blinded technician. Thrombin receptor-activating peptide 15 mol/L was the primary agonist used at serial time points. Tracings were verified by 
Clinical Outcomes
The primary safety endpoint was the proportion of subjects with major bleeding according to the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) bleeding classification (defined as significantly disabling bleeding, bleeding requiring Ն2 U of red blood cells or equivalent, intracranial or intraocular hemorrhage, bleeding requiring inotropes or surgical intervention, or bleeding leading to death) up to 12 weeks of treatment. CURE minor bleeding was defined as hemorrhage not meeting the CURE definition for major bleeding and leading to the interruption of study drug. 9 Bleeding endpoints were also classified according to the Thrombolysis in Myocardial Infarction (TIMI) bleeding definitions (major, minor, or minimal). 10 Secondary objectives included the effects of atopaxar on major adverse cardiovascular events, including cardiovascular death, MI, stroke, or recurrent ischemia; on platelet function; and on Holter-detected ischemia. Recurrent ischemia was defined as discomfort considered to be probable or definite angina lasting at least 10 minutes (ECG changes were not required). All clinical endpoints were adjudicated by a Clinical Endpoints Committee that was blinded to treatment assignment. Assuming a 5.3% incidence of any CURE bleeding, the trial had 80% power to detect a 50% increase in bleeding with the combined atopaxar group compared with placebo.
Statistical Analysis
Baseline characteristics are presented as means (SDs) or counts and percentages. The incidence of safety and efficacy events is reported for the combined active atopaxar treatment groups, each dose arm, and the placebo group. The incidence was calculated as the number of subjects with an event divided by the number of subjects within a group for each treatment arm. Comparisons between active treatment groups and placebo were assessed as the relative risk with 95% confidence limits based on the Agresti-Min method and accompanied by a 2-sided exact P value. The Cochran-Armitage trend test was used to assess for trends across the active treatment arms.
All efficacy analyses were conducted on an intention-to-treat basis. The primary safety analyses included only those subjects who had taken at least 1 dose of study drug. All tests were 2 sided and conducted at an ␣ϭ0.05 level of significance.
The study was funded by Eisai, Inc. (Tokyo, Japan) and was designed by the Steering Committee in collaboration with the sponsor. Independent Clinical Endpoints Committee adjudication was conducted by the Cleveland Clinic Cardiovascular Coordinating Center. The TIMI Study Group was provided the trial database and independently verified all analyses (C.F.C.). All drafts of the manuscript were written by the academic authors, who take responsibility for its content.
Results
Six hundred and three subjects were randomized to 1 of 4 treatment arms, and 593 subjects took at least 1 dose of study drug ( Figure 2 ). The baseline characteristics of the study population were relatively comparable between the placebo and combined active treatment arms (Table 1) . Imbalances were observed for the incidence of prior MI and peripheral arterial disease across the individual dose groups, but the incidence rates were similar between the active combined and placebo groups. The mean age of the subjects was 62 years, and 32% were women. The qualifying event was non-STelevation MI in 77% of subjects; Ϸ43% of subjects underwent percutaneous coronary intervention, 96% were treated with aspirin, and 82% were treated with clopidogrel or ticlopidine. The use of evidence-based therapies during the course of the trial, including aspirin, thienopyridines, statins, and ␤-blockers, was similar across the treatment groups (Table 1) .
Bleeding Outcomes
Eight adjudicated major bleeds and 9 adjudicated minor bleeds, according to the CURE bleeding classification, occurred during 12 weeks of treatment. The incidence of CURE major or minor bleeding was similar between the combined atopaxar and placebo groups (3.1% [ * Due to a progamming error in the IVRS, 38 subjects in the 100 mg group and 40 subjects in the 200 mg group were erroneously dispensed the 50mg dose of atopaxar at the week 4 visit. Of these individuals, 21 subjects were resupplied with the correct dose of study drug prior to study conclusion. No subjects in the placebo or 50 mg dose arms were affected. [3 of 138], respectively; Pϭ0.63), and there was no doserelated trend (Pϭ0.80; Figure 3 ). Although subgroup sizes were small, there was no evidence of heterogeneity for subjects who were elderly (Ն75 years of age; nϭ70), were women (nϭ188), or had a reduced creatinine clearance (Ͻ60 mL/min; nϭ97). There were no significant differences between the combined active atopaxar and placebo groups in the individual categories of major, minor, minimal, or instrumented bleeds according to the TIMI bleeding criteria ( Figure 3 ).
Efficacy Outcomes
Forty-eight adjudicated major adverse cardiovascular events (including cardiovascular death, MI, stroke, or recurrent ischemia) occurred during the 12-week treatment period ( Figure 4 ). The proportion of subjects who experienced Figure 4) ; however, this difference was not statistically significant. Analyses excluding subjects affected by the resupply error and the person-time major adverse cardiovascular events incidence analysis suggested that there was no significant impact of the resupply error on these analyses. Continuous ECG monitoring by Holter was performed in 561 of randomized subjects (93%). There was a statistically significant 34% reduction in Holter-detected ischemia in the combined active atopaxar treatment groups versus placebo (relative risk, 0.67; 95% confidence interval, 0.48 to 0.94; Pϭ0.02) during the first 48 hours after the 400-mg loading dose.
Platelet Function Testing
A total of 63 patients were enrolled in the platelet function substudy and had an interpretable predose (baseline) aggregation result ( Figure 5 ). Inhibition of platelet aggregation in response to 15 mol/L thrombin receptor-activating peptide agonist was observed in the first 1 to 3 hours after the loading dose in all active atopaxar treatment groups (mean inhibition of platelet aggregation, 74%). At 3 to 6 hours after the loading dose, 90% to 100% subjects in the atopaxar groups had achieved Ͼ80% inhibition of platelet aggregation. During maintenance dosing, a trend toward greater dose-dependent inhibition of platelet aggregation was observed with increasing doses of drug. At week 12, the predose mean inhibition of platelet aggregation was 66.5%, 71.5%, and 88.9% in the 50-, 100-, and 200-mg groups, respectively (P for trendϭ0.07). 
Adverse Effects
A similar percentage of subjects discontinued study drug in the combined active atopaxar treatment group and the placebo group (28.9% and 31.0%, respectively). The proportion of subjects who reported at least 1 adverse event was similar in the combined active atopaxar treatment group and the placebo group (67.3% and 68.1%, respectively). The most commonly reported treatment-related adverse effects were gastrointestinal disorders (6.6% in the combined atopaxar versus 5.8% in the placebo arm), including nausea, constipation, and abdominal pain.
Transient liver function abnormalities were observed in all groups (including placebo) at the time of the qualifying ACS event and resolved by week 2 of treatment. Overall, the incidence of liver function abnormalities did not differ between the combined atopaxar groups and placebo group. Clinically significant alanine aminotransferase elevations (Ն3 times upper limit of normal) after 2 weeks were recorded more frequently with the highest dose of atopaxar (2.2%, 2.2%, and 5.5% for the 50-, 100-, and 200-mg groups, respectively; P for trendϭ0.14) compared with 2.5% in the placebo group (Table 4) . Most liver function abnormalities occurred in the 200-mg arm between weeks 4 and 8 and resolved with continued therapy before week 12 ( Figure 6 ). There were no cases of Hy's law, defined as alanine aminotransferase Ͼ3 times above the upper limit of normal and total bilirubin Ͼ2 times above the upper limit of normal.
During the treatment phase, there was an overall decrease in the mean QTcF (Fridericia's formula) interval in both the placebo and atopaxar groups that was likely explained by relative QTcF prolongation at the time of the ACS. The mean decrease in the QTcF interval was greater in the placebo group than in the combined atopaxar group (Ϫ11.4 versus Ϫ6.4 milliseconds, respectively; Pϭ0.04). This difference was driven mainly by a smaller decrease in the QTc interval in the 100-mg (Ϫ4.5 milliseconds) and 200-mg (Ϫ4.9 milliseconds) groups compared with placebo. There were no known associated cases of syncope or malignant arrhythmias.
Median serum creatinine levels increased slightly throughout the treatment period in all groups, including the placebo group. The incidence of clinically significant abnormal serum creatinine values was similar for the atopaxar and placebo groups. The greatest median increase was observed in the 200-mg group. The median increase from day 4 to week 12 in the placebo group ranged between 2 and 4 mol/L; in the 50-mg arm, between 7 and 10 mol/L; in the 100-mg arm, between 7 and 9 mol/L; and in the 200-mg arm, between 9 and 13 mol/L.
Discussion
The LANCELOT-ACS trial assessed the safety and tolerability of the novel PAR-1 inhibitor atopaxar (E5555) at 3 dose levels (50, 100, and 200 mg daily) after a 400-mg loading dose in patients after ACS. The results of this phase II trial demonstrated that atopaxar significantly reduced Holterdetected ischemia without a clear increase in bleeding compared with placebo. In a focused platelet function substudy, atopaxar achieved rapid and sustained platelet inhibition via the PAR-1 receptor. Although the drug was generally well tolerated, liver transaminase elevation and relative QTc prolongation were observed with the highest doses of atopaxar. Atopaxar is a reversible and orally active small-molecule inhibitor that interferes with thrombin-mediated platelet activation via the PAR-1 receptor. 11 In preclinical animal models, atopaxar significantly prolonged time to occlusion in injured arterial vessels and significantly inhibited neointimal hyperplasia in a balloon-injured carotid artery. It is hypothesized that PAR-1-mediated platelet activation might contribute to the formation of pathological thrombosis but may not be required for formation of the early platelet monolayer in appropriate hemostasis. 8 Thus, it is plausible that PAR-1 antagonists might offer clinical benefit without significantly increasing the risk of bleeding. To that end, atopaxar has demonstrated potent antiplatelet effects without increasing bleeding times in preclinical studies. 12 Furthermore, atopaxar has previously been shown to inhibit the thrombin-mediated release of soluble CD40 ligand from the platelet while allowing ADP-mediated pathways to remain intact. 11 Vorapaxar (SCH 530348), another oral PAR-1 receptor antagonist, 13 is being evaluated in 2 phase III trials, the Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P-TIMI 50; NCT00526474) 14 and the Trial to Assess the Effects of SCH 530348 in Preventing Heart Attack and Stroke in Patients With Acute Coronary Syndrome (TRA-CER; NCT00527943). 15 In January 2011, the joint Data and Safety Monitoring Board for the 2 trials reported an excess of intracranial hemorrhage in patients with a history of stroke. 16 As a consequence, study drug was discontinued in the TRA 2P-TIMI 50 trial for subjects with a history of stroke, but remains ongoing for subjects with a history of MI or peripheral arterial disease. The TRACER trial was stopped prematurely after reaching its prespecified number of primary endpoints. Although vorapaxar and atopaxar share similarities, vorapaxar exhibits a much longer half-life (165 to 311 hours) and achieves 50% recovery of platelet function at 4 weeks after treatment discontinuation. 8 In contrast, atopaxar has an approximate plasma half-life of 22 to 26 hours. Although future evaluation is required, the shorter half-life for atopaxar could offer a theoretical advantage for patients requiring urgent surgery or for those who are actively bleeding. The current phase II trial is underpowered for safety events, including intracranial hemorrhage. A large clinical outcomes study will be required before the safety of atopaxar can be adequately ascertained.
In the LANCELOT-ACS trial, the overall rate of bleeding was lower than anticipated. No major bleeding events occurred in the placebo group despite the use of standard antithrombotic and antiplatelet therapy for patients with ACS. This result notwithstanding, the overall incidence of bleeding was similar between the placebo and combined atopaxar treatment groups. The frequency of CURE major bleeds was numerically higher in the combined atopaxar group compared with placebo, but the frequency of minor or instrumented bleeds was lower for patients on atopaxar than in the placebo arm; these differences did not achieve statistical significance.
Because the LANCELOT-ACS trial was not powered to assess clinical efficacy, the efficacy data should be inter- preted with caution. The overall incidence of cardiovascular death, MI, stroke, or recurrent ischemia was similar for patients treated with atopaxar and placebo. The incidence of CV death, MI, or stroke was 5.63% in the placebo group and 3.25% in the combined atopaxar group (Pϭ0.20). Although underpowered to achieve statistical significance, this possible signal of clinical efficacy was supported mechanistically by a significant 33% reduction in the incidence of ischemia by Holter monitoring in the first 48 hours after a 400-mg loading dose of atopaxar. To the best of our knowledge, this is the first time that an oral antiplatelet drug has been shown to significantly reduce ischemia as detected by Holter monitor, a surrogate endpoint for clinical events. Importantly, these findings were observed on a background of guidelinerecommended therapies, including ␤-blockers, aspirin, and thienopyridines. These results may also suggest that Holter monitoring could be an important means to detect efficacy signals in future phase II studies of novel compounds. A clear dose-dependent trend for either efficacy or bleeding was not observed with increasing doses of atopaxar. In particular, subjects randomized to the 100-mg dose experienced the highest incidence of both major adverse cardiovascular events and bleeding. It is plausible that these findings are explained by play of chance or possibly by differences in baseline characteristics between randomized treatment arms.
To that end, a larger percentage of subjects in the 100-mg group had a history of peripheral artery disease, carotid artery disease, and previous transient ischemic attack or nonhemorrhagic stroke. In addition, the majority of bleeding and major adverse cardiovascular events occurred early after randomization; therefore, the use of a common loading dose in all active groups may have attenuated a dose-dependent signal. The present study has limitations that warrant consideration. Because the bleeding rates for the trial were lower than anticipated, we cannot exclude a small or moderate increase in bleeding with atopaxar compared with placebo. Although atopaxar did not increase the incidence of instrumented bleeding, the overall rate of percutaneous coronary intervention for an ACS trial was relatively low. In addition, as a result of a programming error in the interactive voice response system, some subjects were erroneously dispensed the 50-mg dose of drug in the 100-and 200-mg dosing arms at the 1-month visit. Thus, the relationship between escalating doses and safety or efficacy signals could have been partly attenuated. However, all analyses were verified in a population that excluded those subjects affected by the resupply error. Furthermore, all major bleeding events occurred during the first month after randomization and before the incorrect drug dispensation. Treatment duration was relatively short, and further information on longer-term tolerability is needed.
Conclusions
This study demonstrated that atopaxar was generally well tolerated, especially at the 50-mg treatment dose. However, relative QTcF prolongation and liver function abnormalities were observed more frequently with the highest doses of atopaxar, a finding that is consistent with the results of the smaller phase II studies conducted in Japan. 17 The LANCELOT-ACS trial is the first international phase II trial to evaluate a PAR-1 receptor antagonist in patients after ACS. Potential signals of efficacy without a clear increase in evident bleeding support a possible role for atopaxar in the treatment of patients after ACS and support at serial time points during the treatment phase at or beyond 2 weeks. Three subjects discontinued the study drug because of liver function abnormalities. An ALT elevation was seen more frequently in the 200-mg dose group between weeks 4 and 8 but returned to within normal limits on continued therapy by week 12. There were no cases of Hy's law.
the concept of the PAR-1 receptor as a possible key target for inhibition.
